JAK3 and pancreatic adenocarcinoma: This pattern of gene regulation highly overlaps with several drugs that could be involved in the treatment of PAAD patients (Table S15), including BRD-K50836978 (purvalanol-a), BRD-K71035033 (masitinib), BRD-K04546108 (JAK3-inhibitor-VI), BRD-K52522949 (NCH-51), BRD-K56334280 (amonafide), and BRD-K22503835 (scriptaid) (Figure 8C-H).